StockWatch
·

Godrej Agrovet Ltd Q1 FY26 Results

GODREJAGROQ1 FY26 Results
Filing
MetricValue ( Cr)vs Q4 FY25
Revenue2.6K22.5%
Total Income2.6K22.3%
Expenditure2.4K17.6%
PBT188.19153.5%
Net Profit148.83125.2%
OPM10.32%3.45pp
NPM5.67%2.59pp
EPS8.35126.9%
View full financials

Godrej Agrovet Reports Strong Q1 FY26 Performance with 20% Revenue Growth in Astec LifeSciences

06 Aug 2025 · 6 Aug 2025, 07:03 pm

Summary

Godrej Agrovet Limited has announced its financial results for the first quarter ended June 30, 2025, reporting a 20% revenue growth in Astec LifeSciences. The company's profitability, operational efficiencies, and volume growth have improved significantly, despite some challenges in certain segments.

Key Highlights

  1. 1

    Q1 FY26 revenues grew by 20% Y-o-Y

  2. 2

    EBITDA margin increased by ~11% Y-o-Y

  3. 3

    PBT margin increased by ~11% Y-o-Y

  4. 4

    PAT margin increased by ~4% Y-o-Y

  5. 5

    Astec LifeSciences reported a growth in revenue of ~31%

  6. 6

    Animal Feed volume growth recorded across all key categories

  7. 7

    Vegetable Oil segment revenue and margins improved significantly

  8. 8

    Crop Protection (Standalone) segment revenue grew marginally

  9. 9

    Dairy segment revenue improved by ~31% y-o-y

  10. 10

    Godrej Foods Limited poultry & processed foods business recorded a decline in revenues and EBITDA

Management Comments

M

Mr. B. S. Yadav

Managing Director, Godrej Agrovet Limited

Godrej Agrovet Limited reported strong financial performance for Q1 FY26 with notable growth in revenues, profitability, and operational efficiencies. The growth in profitability was mainly driven by robust volumes & improved operational efficiencies in the Vegetable Oils business supported by significant reduction in losses in Astec Lifesciences. In the Animal Feed business, while overall volume growth was a healthy 8%, segment revenue & underlying margins were flat due to lower realizations. In the domestic Crop Protection business, the segment revenue grew marginally by 5% and segment margins were similar year-on-year due to lower net realizations in respect of in-house & in-licensing categories. In our Dairy business, early rains and higher milk procurement prices impacted profitability while segment revenue was flat. In our Poultry & Processed foods business, revenues declined primarily due to lower volumes in live bird category which is in line with our strategy to reduce salience in this category & profitability was impacted due to muted realizations in live bird category. While the branded revenues were flat, contribution margins improved year-on-year. Astec LifeSciences reported a growth in revenue of ~ 31% on account of higher volumes in both Enterprise & CDMO categories. EBITDA losses reduced significantly primarily on account of lower raw material costs and higher volumes.

Informational and educational content only. Not investment advice.